I think its very possible that they may not end up
Post# of 30028
Now that the toxics have been removed, they can negotiate much easier with potential partners. Plus they needed to have a plan in place to give them leverage in their negotiations. If a partner sees the company has no options and need the partner to do a trial, they will try to steal the asset, so the Company needs to show them that they don't need the partner to do a trial.
If they can bring on a partner for ESS or Lympro, which I think are the 2 most likely assets to partner in the near term, then hopefully the share price rises to a level which allows a lot of options and doing an IPO may not even be necessary.